Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Formoterol--where does it fit in the current guidelines?

R Pauwels1

  • 1Department of Respiratory Diseases, University Hospital Ghent, Belgium. romain.pauwels@rug.ac.be

Respiratory Medicine
|September 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European consensus on patient contact shielding.

Radiography (London, England : 1995)·2021
Same author

Efficacy of a novel intradermal <i>Lawsonia intracellularis</i> vaccine in pigs against experimental infection and under field conditions.

Porcine health management·2020
Same author

Radiological Protection in Cone Beam Computed Tomography (CBCT). ICRP Publication 129.

Annals of the ICRP·2015
Same author

Optimization of dental CBCT exposures through mAs reduction.

Dento maxillo facial radiology·2015
Same author

Effect of exposure parameters and voxel size on bone structure analysis in CBCT.

Dento maxillo facial radiology·2015
Same author

Comparison of mandibular bone microarchitecture between micro-CT and CBCT images.

Dento maxillo facial radiology·2015

Asthma treatment guidelines are not being met, leading to poor patient outcomes. Formoterol, a fast- and long-acting beta2-agonist, shows promise for improving asthma management and patient compliance.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Asthma incidence is rising despite advances in treatment and understanding.
  • Current asthma management strategies often fall short of treatment guideline objectives.
  • Patient non-compliance and differing perceptions between patients and physicians hinder effective asthma control.

Purpose of the Study:

  • To evaluate the effectiveness of formoterol as a first-line reliever medication for asthma.
  • To explore the potential of formoterol to improve patient compliance through a single inhaler for maintenance and as-needed therapy.
  • To assess the safety and efficacy of as-needed formoterol in a real-life setting.

Main Methods:

  • Analysis of existing asthma treatment guidelines and patient surveys in Europe and the USA.
  • Review of the pharmacological properties of formoterol, a unique fast- and long-acting beta2-agonist.

Related Experiment Videos

  • Ongoing large-scale, randomized, real-world effectiveness study (RELIEF) involving 18,000 patients globally.

    • Main Results:

    • Current asthma treatment guidelines are not consistently met, evidenced by high exacerbation rates and frequent reliever medication use.
    • Formoterol's dual action offers potential for improved patient compliance by simplifying inhaler use.
    • The RELIEF study is expected to provide robust data on formoterol's real-world safety and efficacy as a reliever.

    Conclusions:

    • There is a significant gap between asthma treatment guidelines and real-world patient outcomes.
    • Formoterol presents a promising therapeutic option to enhance asthma management and patient adherence.
    • The findings from the RELIEF study are anticipated to support formoterol's inclusion as a first-line reliever in future asthma treatment guidelines.